Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Hot on the trail in the TME: Clues from a trilogy of checkpoint inhibitor trials in nasopharyngeal cancer CANCER CELL Ma, B. Y., Le, Q. 2023; 41 (6): 1006-1008

Abstract

In this issue of Cancer Cell, Yang et al. report the third in a series of phase III trials that demonstrates the survival benefit of combining a PD-1 inhibitor with chemotherapy in nasopharyngeal cancer. A gene expression analysis identifies "hot" and "cold" tumor signatures with prognostic and predictive significance.

View details for DOI 10.1016/j.ccell.2023.04.013

View details for Web of Science ID 001024475200001

View details for PubMedID 37207653